> Details

Pancisi, Elena; Granato, Anna Maria; Scarpi, Emanuela; Ridolfi, Laura; Carloni, Silvia; Moretti, Cinzia; Guidoboni, Massimo; De Rosa, Francesco; Pignatta, Sara; Piccinini, Claudia; Soldati, Valentina; Calabrò, Luana; Framarini, Massimo; Stefanelli, Monica; Bulgarelli, Jenny; Tazzari, Marcella; Fanini, Francesca; Petrini, Massimiliano

Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
  • Contributor: Pancisi, Elena; Granato, Anna Maria; Scarpi, Emanuela; Ridolfi, Laura; Carloni, Silvia; Moretti, Cinzia; Guidoboni, Massimo; De Rosa, Francesco; Pignatta, Sara; Piccinini, Claudia; Soldati, Valentina; Calabrò, Luana; Framarini, Massimo; Stefanelli, Monica; Bulgarelli, Jenny; Tazzari, Marcella; Fanini, Francesca; Petrini, Massimiliano
  • imprint: MDPI AG, 2022
  • Published in: Vaccines
  • Language: English
  • DOI: 10.3390/vaccines10070999
  • ISSN: 2076-393X
  • Keywords: Pharmacology (medical) ; Infectious Diseases ; Drug Discovery ; Pharmacology ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:p>Advanced therapy medical products (ATMPs) are rapidly growing as innovative medicines for the treatment of several diseases. Hence, the role of quality analytical tests to ensure consistent product safety and quality has become highly relevant. Several clinical trials involving dendritic cell (DC)-based vaccines for cancer treatment are ongoing at our institute. The DC-based vaccine is prepared via CD14+ monocyte differentiation. A fresh dose of 10 million DCs is administered to the patient, while the remaining DCs are aliquoted, frozen, and stored in nitrogen vapor for subsequent treatment doses. To evaluate the maintenance of quality parameters and to establish a shelf life of frozen vaccine aliquots, a stability program was developed. Several parameters of the DC final product at 0, 6, 12, 18, and 24 months were evaluated. Our results reveal that after 24 months of storage in nitrogen vapor, the cell viability is in a range between 82% and 99%, the expression of maturation markers remains inside the criteria for batch release, the sterility tests are compliant, and the cell costimulatory capacity unchanged. Thus, the data collected demonstrate that freezing and thawing do not perturb the DC vaccine product maintaining over time its functional and quality characteristics.</jats:p>
  • Access State: Open Access